Enterprise Value
48.77M
Cash
21.44M
Avg Qtr Burn
-7.979M
Short % of Float
4.13%
Insider Ownership
5.97%
Institutional Own.
22.97%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
POSIMIR® (bupivacaine extended-release solution) Details Post operative acute pain | Approved Quarterly sales | |
DUR-928, larsucosterol Details Liver disease, Alcoholic hepatitis | Phase 2b Update |